New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | all day >>
07:05 EDTMOVMovado raises quarterly dividend 10% to 11c per share
Subscribe for More Information
07:05 EDTPNXPhoenix Companies reports Q4 EPS ($24.40) vs. ($24.92) last year
Reports Q4 revenue $440.4M vs. $463.8M last year.
07:05 EDTXELXcel Energy management to meet with UBS
Subscribe for More Information
07:05 EDTLGFLionsgate partners with Dubai Parks and Resorts
Subscribe for More Information
07:04 EDTMOVMovado sees FY16 EPS $2.00-$2.10, consensus $1.89
Sees FY16 revenue $590M-$600M, consensus $602.63M. Sees gross margin roughly 53.5%, operating income $72M-$75M. Sees 30% effective tax rate. Company sees recording $3M-$4M charge related to operating efficiency initiatives.
07:04 EDTMTLMechel upgraded to Hold from Sell at Deutsche Bank
Subscribe for More Information
07:03 EDTACFCAtlantic Coast Financial says OCC terminates consent order against bank
Subscribe for More Information
07:03 EDTATRS, TEVAAntares Pharma announces FDA approval of TEV-TROPIN
Antares Pharma announced that Ferring Pharmaceuticals has received FDA approval of a name change enabling its newly acquired recombinant human growth hormone to be marketed in the U.S. as Zomacton for injection, and the needle-free delivery system to be marketed in the U.S. as ZOMA-Jet. Ferring also received approval from the FDA to market the 10 mg needle-free injector device which, along with certain consumables, is supplied by Antares to Ferring. Ferring purchased the U.S. rights to Zomacton, formerly TEV-TROPIN, and to ZOMA-Jet, formerly Tjet, in December 2014 from Teva Pharmaceutical (TEVA). Ferring developed and has marketed Zomacton outside of the U.S. since 1988 and in 47 countries globally.
07:03 EDTCSIQ, SHCAYCanadian Solar completes acquisition of Recurrent Energy from Sharp
Subscribe for More Information
07:03 EDTJCI, CBGJohnson Controls to sell its GWS business to CBRE Group for $1.475B
Subscribe for More Information
07:03 EDTMXPTMaxPoint Interactive initiated with a Buy at Deutsche Bank
Target $13.
07:03 EDTENH, MRHEndurance Specialty to acquire Montpelier Re for $40.24 in cash and stock
Subscribe for More Information
07:02 EDTCBG, JCICBRE Group, Johnson Controls enter into 10-year strategic relationship
Subscribe for More Information
07:02 EDTMOVMovado reports Q4 EPS 40c, consensus 20c
Reports Q4 revenue $133.91M, consensus $134.31M.
07:02 EDTCBG, JCICBRE to acquire Johnson Controls' Global WorkPlace Solutions business for $1.5B
Subscribe for More Information
07:01 EDTRAIReynolds American volatility at six-year high
Subscribe for More Information
07:00 EDTBCRXBioCryst awarded $35M contract by BARDA for development of BCX4430
BioCryst Pharmaceuticals announced that the Biomedical Advanced Research and Development Authority, or BARDA, within the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, or ASPR, has awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This ASPR/BARDA contract includes a base contract of $12.1M to support BCX4430 drug manufacturing, as well as $22.9M in additional development options that can be exercised by the Government, bringing the potential value of the contract to $35.0M. Filoviruses represent serious threats to national security and the U.S. Government has made this a top priority for medical countermeasure development.
07:00 EDTMXPTMaxPoint Interactive initiated with an Outperform at William Blair
Subscribe for More Information
06:59 EDTECHOEcho Global downgraded at BB&T
Subscribe for More Information
06:58 EDTMOSMosaic raises annual dividend to $1.10 per share from $1.00 per share
Mosaic announced that its board has approved an increase to the company's annual dividend to $1.10 from $1.00 per share effective with the next declaration, expected to be in May.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | all day >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use